Abstract

Dr. Mark L. Batshaw is a distinguished pediatrician, researcher, and educator whose work has transformed the landscape of developmental medicine and rare disease research. Renowned for his pioneering contributions to the understanding and treatment of urea cycle disorders, Dr. Batshaw helped develop innovative therapies that have significantly improved survival and quality of life for affected children. His leadership at Children’s National Hospital and his role in the NIHfunded Rare Disease Clinical Research Network have shaped collaborative research models now used worldwide. Beyond his scientific achievements, Dr. Batshaw is widely respected for his authorship of Children with Disabilities, a foundational textbook that has guided generations of clinicians in caring for children with developmental and genetic conditions. His personal experiences with learning challenges cultivated a lifelong commitment to compassion, advocacy, and patientcentered care. Through his research, mentorship, and dedication to advancing pediatric science, Dr. Batshaw has left an enduring legacy that continues to influence modern clinical practice and inspire future healthcare professionals. Key Message: A pioneer in developmental pediatrics, Dr. Mark L. Batshaw revolutionized the understanding and treatment of childhood genetic and metabolic disorders.

• 1.   Brusilow S.W., Batshaw M.L., Yudkoff M. Urea cycle enzymes. Annu Rev Biochem. 1986; 55: 535-65.
• 2.   Brusilow S.W., Maestri N.E. Urea cycle disorders: diagnosis, pathophysiology, and therapy. Adv Pediatr. 1996; 43: 127-70.
• 3.   Maestri N.E., Clissold D.B., Brusilow S.W. Neonatal onset ornithine transcarbamylase deficiency: A retrospective analysis. J Pediatr. 1999; 134(3): 268-72.
• 4.   Batshaw M.L., Walser M., Brusilow S.W. Alternative pathway therapy for urea cycle disorders. N Engl J Med. 1982; 306(23): 1387-92.
• 5.   Batshaw M.L., Tuchman M., Summar M., Seminara J. A longitudinal study of urea cycle disorders. Mol Genet Metab. 2014; 113(1-2): 127-30.
• 6.   Lee B., Goss J., Barshop B., Yu H., Zahl T., Bartz D., et al. Chronic treatment of urea cycle disorders with glycerol phenylbutyrate. Mol Genet Metab. 2010; 100(3): 229-34.
• 7.   Raper S.E., Chirmule N., Lee F.S., Wivel N.A., Bagg A., Gao G.P., et al. Fatal systemic inflammatory response after adenoviral gene therapy for OTC deficiency. Mol Genet Metab. 2003; 80(1-2): 148-58.
• 8.   Wilson J.M. Lessons learned from the Gelsinger case: ethical considerations in human gene therapy. Hum Gene Ther. 2009; 20(9): 848-56.
• 9.   Wang L., Wang H., Bell P., McCarter R.J., He J., Calcedo R., et al. Systemic AAV8mediated gene therapy for ornithine transcarbamylase deficiency. Mol Ther. 2010; 18(4): 7 13-21.
• 10.   Cunningham S.C., Putt W., Arnell H., Taylor M, Alexander I.E. Gene therapy for urea cycle defects: current progress and future prospects. J Inherit Metab Dis. 2020; 43(1): 41-55.
• 11.   Yang Y., Wang L., Bell P., McMenamin D., He Z., White J., et al. A dual-vector CRISPR/Cas9 system for OTC gene correction in newborn mice. Nat Commun. 2016; 7: 11900.
• 12.   Batshaw M.L., Roizen N.J., Lotrecchiano G., editors. Children with Disabilities. 8th ed. Baltimore: Paul H. Brookes Publishing; 2019.
• 13.   Batshaw M.L., editor. The Child with Special Needs: Developmental and Behavioral Pediatrics. Baltimore: Williams & Wilkins; 1993.
• 14.   Vieira K.A., Rosenberg L.A., Dias T., McCarter R., Batshaw M.L. Personal reflections on learning disabilities in medicine. Pediatrics. 2014; 133(5): 789-92.
• 15.   DeBenedictis R., Kellogg M., Batshaw M.L. The evolution of developmental pediatrics: contributions of the Kennedy Krieger Institute. Dev Med Child Neurol. 2012; 54(3): 198-204.

Data Sharing Statement

Funding